SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) December 16, 2004
Corcept Therapeutics Incorporated
(Exact Name of Registrant as Specified in Charter)
| Delaware | 000-50679 | 77-0487658 | ||
| (State or other jurisdiction of incorporation) |
(Commission File No.) | (I.R.S. Employer Identification No.) |
275 Middlefield Road, Suite A
Menlo Park, California 94025
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 327-3270
(Former Name or Former Address, if changed since last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
(d) On December 16, 2004, Steven H. Kapp resigned from the Board of Directors of Corcept Therapeutics Incorporated (the “Company”), effective December 31, 2004. Mr. Kapp is a limited partner at Maverick Capital, Ltd., an investment adviser to private investment funds (“Maverick”).
Item 8.01 Other Events
In December 2004, David B. Singer, a director of the Company, joined Maverick Capital Ltd.. Maverick beneficially owns approximately 9.4% of the Company’s issued and outstanding common stock.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
| CORCEPT THERAPEUTICS INCORPORATED | ||
| By: | /s/ Fred Kurland | |
| Name: | Fred Kurland | |
| Title: | Chief Financial Officer | |
Date: December 21, 2004